EarningsQ2 2026 Earnings Report
MX:LH Q2 2026 EPS Results
Actual EPS$90.71
Consensus EPS$86.87
Beat/MissBeat by +$3.84
One Year Ago EPS$79.08
MX:LH Q2 2026 Revenue Results
Actual Revenue$67.82B
Expected Revenue$67.43B
Beat/MissBeat by +$395.07M
YoY Revenue Growth+5.78%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
MX:LH Upcoming Earnings
Labcorp Holdings's next earnings date is estimated for October 28, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:LH Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a strong operational and financial quarter: revenue growth, margin expansion, double-digit adjusted EPS growth, raised guidance, robust BLS backlog and book-to-bill, and multiple product/partnership launches. Headwinds highlighted were a meaningful quarter-over-quarter drop in free cash flow (timing and capex), a modest ACA-related volume headwind (~30 bps), prior and improving Early Development softness, higher patient-pay mix, and elevated absolute debt with relatively low cash on hand. On balance the positives around revenue, margins, guidance increases, product/market progress, and capital returns materially outweigh the cited challenges.Company Guidance
Enterprise Revenue Growth
Revenue grew 5.8% year-over-year to $3.7 billion ($3.7B reported; CEO cited 6%), with organic revenue growth of 4.2%, net acquisitions contributing 1.2%, and foreign currency adding 0.4%.
Margin Expansion and EPS Growth
Enterprise adjusted operating margin expanded 70 basis points to 15.8%. Adjusted EPS rose 14.9% to $4.99. Full-year adjusted EPS guidance was raised (range $18.10–$18.55) with the midpoint up $0.30 and an implied >11% growth at midpoint.
Diagnostics Segment Performance
Diagnostics revenue increased 5.5% to $2.9 billion. Organic Diagnostics growth was 3.6% (1.8% accession/volume + 1.8% favorable price/mix). Diagnostics adjusted operating income was $523 million (18% margin), up from $483 million (17.6%), a margin expansion of ~50 basis points.
Biopharma Laboratory Services (BLS) Strength
BLS revenue rose 6.5% to $836 million. Organic constant-currency growth was 6.2%; Central Labs organic growth 7.6%, Early Development organic growth 2.7%. BLS adjusted operating income improved to $142 million (17% margin) from $123 million (15.7%), a ~130 basis point margin expansion. Backlog was $8.7 billion with ~$2.7 billion expected to convert in next 12 months.
Strong Book-to-Bill and Central Labs Momentum
Quarterly BLS book-to-bill was 1.14 and trailing 12-month book-to-bill 1.03, driven by Central Labs strength and supportive pipeline / RFP activity.
Capital Allocation and Shareholder Returns
Invested $226 million in acquisitions, repurchased $354 million of shares, and paid $59 million in dividends. Board increased share repurchase authorization by $1.0 billion to $1.4 billion total.
Product, Partnership and Commercial Progress
Notable launches and partnerships: nationwide launch of ColoSense (FDA‑approved RNA-based at-home colorectal screening), Medicare coverage for NASHnext (mid-August), expanded access to Roche prostate cancer companion diagnostic, DPYD genotyping added, myOLARIS-KTdx agreement, DoD contract award, and expanded Epic collaboration (6,500+ tests on Epic Aura).
Consumer & Digital Momentum
Consumer (Labcorp OnDemand) delivered double-digit growth; launched Marker by Labcorp genetic health panel and Canada's first at-home fertility/testosterone self-collection; AI-powered MyLabcorp app has been downloaded by millions, improving access and experience.
Recognition and Strategic Progress
Company recognized by Time (one of the world's most impactful companies) and Wall Street Journal (Best Companies for the Future). Management reiterated execution on Launchpad initiative and tech/AI investments supporting long-term profitable growth.
MX:LH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed